Response to B-cell depletion therapy for lupus predicted by biomarkers
Patients with active refractory systemic lupus erythematosus (SLE) and an expanded autoantibody profile with raised BLyS levels have shorter responses to B cell depletion therapy (BCDT), according to a recent investigation....
Want to read complete article? Please Sign in or Register.